TY - JOUR
T1 - Elevated levels of urinary PGE-M are found in tobacco users and indicate a poor prognosis for oral squamous cell carcinoma patients
AU - Kekatpure, Vikram D.
AU - Bs, Naveen
AU - Wang, Hanhan
AU - Zhou, Xi Kathy
AU - Kandasamy, Chandramohan
AU - Sunny, Sumsum P.
AU - Suresh, Amritha
AU - Milne, Ginger L.
AU - Kuriakose, Moni Abraham
AU - Dannenberg, Andrew J.
N1 - Publisher Copyright:
©2016 AACR.© 2016 American Association for Cancer Research.
PY - 2016/6
Y1 - 2016/6
N2 - Cyclooxygenase-2 (COX-2)-derived prostaglandin E2 (PGE2) plays a role in the development and progression of epithelial malignancies.Measurements of urinary PGE-M, a stablemetabolite of PGE2, reflect systemic PGE2 levels.Here, we investigatedwhether urinary PGE-M levels were elevated in healthy tobacco users and in patients with oral squamous cell carcinoma (OSCC). Median urinary PGE-M levels were increased in healthy tobacco quid chewers [21.3 ng/mgcreatinine (Cr); n=33; P=0.03] and smokers (32.1 ng/mg Cr; n =31; P < 0.001) compared with never tobacco quid chewers-never smokers (18.8 ng/mg Cr; n =30). Urinary PGE-M levels were also compared in OSCC patients versus healthy tobacco users. An approximately 1-fold increase inmedian urinary PGE-M level was found in OSCC patients (48.7 ng/mg Cr, n =78) versus healthy controls (24.5 ng/mg Cr, n =64; P < 0.001). We further determined whether baseline urinary PGE-M levels were prognostic in OSCC patients who underwent treatment with curative intent.A nearly 1-fold increase in baseline urinaryPGE-M levels (64.7 vs. 33.8 ng/mg Cr, P < 0.001) was found in the group of OSCC patients who progressed (n =37) compared with the group that remained progression free (n=41). Patients with high baseline levels of urinary PGE-M had both worse disease-specific survival [HR, 1.01 per unit increase; 95% confidence interval (CI), 1.01- 1.02; P < 0.001] and overall survival (HR, 1.01 per unit increase; 95% CI, 1.00-1.02; P =0.03). Taken together, our findings raise the possibility that NSAIDs, prototypic inhibitors of PGE2 synthesis, may be beneficial for reducing the risk of tobacco-related aerodigestive malignancies or treating OSCC patients with high urinary PGE-M levels. Cancer Prev Res; 9(6); 428-36.
AB - Cyclooxygenase-2 (COX-2)-derived prostaglandin E2 (PGE2) plays a role in the development and progression of epithelial malignancies.Measurements of urinary PGE-M, a stablemetabolite of PGE2, reflect systemic PGE2 levels.Here, we investigatedwhether urinary PGE-M levels were elevated in healthy tobacco users and in patients with oral squamous cell carcinoma (OSCC). Median urinary PGE-M levels were increased in healthy tobacco quid chewers [21.3 ng/mgcreatinine (Cr); n=33; P=0.03] and smokers (32.1 ng/mg Cr; n =31; P < 0.001) compared with never tobacco quid chewers-never smokers (18.8 ng/mg Cr; n =30). Urinary PGE-M levels were also compared in OSCC patients versus healthy tobacco users. An approximately 1-fold increase inmedian urinary PGE-M level was found in OSCC patients (48.7 ng/mg Cr, n =78) versus healthy controls (24.5 ng/mg Cr, n =64; P < 0.001). We further determined whether baseline urinary PGE-M levels were prognostic in OSCC patients who underwent treatment with curative intent.A nearly 1-fold increase in baseline urinaryPGE-M levels (64.7 vs. 33.8 ng/mg Cr, P < 0.001) was found in the group of OSCC patients who progressed (n =37) compared with the group that remained progression free (n=41). Patients with high baseline levels of urinary PGE-M had both worse disease-specific survival [HR, 1.01 per unit increase; 95% confidence interval (CI), 1.01- 1.02; P < 0.001] and overall survival (HR, 1.01 per unit increase; 95% CI, 1.00-1.02; P =0.03). Taken together, our findings raise the possibility that NSAIDs, prototypic inhibitors of PGE2 synthesis, may be beneficial for reducing the risk of tobacco-related aerodigestive malignancies or treating OSCC patients with high urinary PGE-M levels. Cancer Prev Res; 9(6); 428-36.
UR - http://www.scopus.com/inward/record.url?scp=84973091554&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84973091554&partnerID=8YFLogxK
U2 - 10.1158/1940-6207.CAPR-15-0412
DO - 10.1158/1940-6207.CAPR-15-0412
M3 - Article
C2 - 27045033
AN - SCOPUS:84973091554
SN - 1940-6207
VL - 9
SP - 428
EP - 436
JO - Cancer Prevention Research
JF - Cancer Prevention Research
IS - 6
ER -